Technology

Technology

Chondrogenix leverages Mogrify's direct cell reprogramming platform, MOGRIFY®, a systematic means of identifying the key regulatory switches, such as an optimal combination of transcription factors, required to drive cell identity. The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct trans-differentiation between a mature cell type to another mature cell type.

Chondrogenix will apply this approach to develop a safe, efficient and scalable source of mature and functional chondrocytes (cartilage cells) to ultimately be used in the clinic to enhance the already approved autologous chondrocyte implantation (ACI) therapy and create additional allogeneic and in vivo reprograming therapies for the treatment of osteoarthritis and other musculoskeletal conditions.

Preliminary morphological characterization of Chondrogenix chondrocytes converted from fibroblasts

Chondrogenix chondrocytes express key marker genes (collagen II, aggrecan and SOX9) at the mRNA level.